Latest Updates

Solitary Fibrous Tumors

Shefali Chopra, MD, James S Hu, MD, Gino K In, MD, Lawrence R Menendez, MD, Dakshesh Patel, MD, Omar Ragab, MD, Stephen F Sener, MD, William W Tseng, MD
    • Identification of the NAB2-STAT6 fusion as a key genetic aberration in SFTs
    • Recognition of subsets of SFTs with more aggressive clinical behavior
    • Development of a simple risk assessment model

Solitary Fibrous Tumors

Shefali Chopra, MD, James S Hu, MD, Gino K In, MD, Lawrence R Menendez, MD, Dakshesh Patel, MD, Omar Ragab, MD, Stephen F Sener, MD, William W Tseng, MD
    • Identification of the NAB2-STAT6 fusion as a key genetic aberration in SFTs
    • Recognition of subsets of SFTs with more aggressive clinical behavior
    • Development of a simple risk assessment model

Infertility Treatment: Ovulation Induction and Insemination

Alan H. DeCherney, MD, Quinton Katler, MD, Jessica R Zolton, DO
    • PCOS Letrozole is considered as the first-line treatment for ovulation induction for patients with PCOS.
    • Luteal support: Luteal progesterone support is beneficial to patients undergoing gonadotropin stimulation and intrauterine insemination
    • Unexplained Infertility: Gonadotropin treatment is associated with a significantly elevated risk of multiple gestations gestations

Management of Non–Muscle-Invasive Bladder Cancer

Peter C Black , MD
    • Molecular characterization of NMIBC by RNA sequencing has revealed molecular subtypes similar to muscle-invasive bladder cancer.
    • Fluorescent cystoscopy in combination with white light cystoscopy at the time of transurethral bladder tumor resection reduces the risk of subsequent bladder tumor recurrence.
    • Maintenance intravesical BCG therapy can be discontinued after 12 months in patients with intermediate-risk NMIBC but should be continued for 36 months in patients with high-risk NMIBC.
    • The refinement of the definition of the “BCG refractory” and its replacement with the term “BCG unresponsive” by an FDA-AUA panel has contributed to active drug development and clinical trials in this disease state. 

Nutrition and Fetal Origins of Diseases in Adults

Amanda K Barks, Michael K Georgieff, MD, Anne Maliszewski-Hall, MD, Phu V Tran, PhD

    Nutrition for the Healthy Adult

    Marijane G. Staniec, MS, RD/LDN, CNSC
      • Latest recommendations for added sugar
      • New guidelines about dietary cholesterol—a license to consume as much as we want?
      • The latest about processed meat; is any amount safe?
      • Shift from single nutrients to whole foods and patterns of eating
      • Using anthropometrics in the primary care setting to determine adiposity

    Energy Balance, Exercise, and Cancer Risk

    Elaine B Trujillo, MS, RD
      • Obesity is the leading modifiable cause of cancer in the United States.
      • Body Mass Index (BMI) as a measurer of body fatness has limitations in the cancer population.
      • Dual-energy x-ray absorptiometry, bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging may be used more frequently in cancer patients.
      • Cancer patients with elevated BMIs have improved survival compared with normal-weight patients.

    Severe Traumatic Brain Injury

    Ryan Martin, MD
      • A multidisciplinary, evidence-based, protocol-directed approach continues to be recommended for the treatment of severe traumatic brain injury.
      • Treatment of severe traumatic brain injury is performed through a systematic, tiered approach, with escalation of therapy in the setting of refractory elevated intracranial pressure.
      • Role of decompressive craniectomy for the control of refractory elevated intracranial pressure remains controversial and is not clearly associated with improved outcomes.
      • Early use of hypothermia to control intracranial pressure is associated with higher rates of mortality.
    « Previous | Next »
    Updates per yearSpecialty updatesNumber of sections